Sentences with phrase «with drug development»

«One of the ways to truly realize the full value of human genetics, is to make our research synergistic with drug development efforts where target discovery, validation and prioritization efforts can be accelerated,» said Kari Stefansson, M.D., Dr. Med., founder and CEO at deCODE Genetics.

We are advancing the fight against these rare tumors by developing biological models to help with drug development and to share with scientists worldwide.

I heard it at a luncheon that was focused on the issues with the drug development pipeline.

CASIS's mission is to encourage «use of this unparalleled platform for innovation» — and Merck is taking this to heart by experimenting with drug development in the realm of microgravity.

Not exact matches

Zymeworks, meanwhile, went through a number of lean years; investors in Canada were still more comfortable with a development model that produced widely applicable chemical drugs.

«Expanding our collaboration with Banner Alzheimer's Institute stands testament to our belief that preventing amyloid buildup is one of the most promising approaches to treating Alzheimer's disease,» said Novartis» chief medical officer, global head of drug development, and soon - to - be CEO Dr. Vas Narasimhan in a statement.

With a critical mass of 450,000 patients annually among them, the six centers have agreed to combine their efforts on planning clinical trials in immunotherapy, recruit patients quickly, and share the information learned — which could be the single biggest factor in speeding up drug development.

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

JOHNSON & JOHNSON PARTNERS TO SPEED ALZHEIMER»S DRUG DEVELOPMENT The drug development arm of Johnson & Johnson (JNJ) has teamed up with an medical research facility called the Sanford - Burnham Institute in the hopes that the partnership will shorten the path to getting new Alzheimer's treatments FDA approDRUG DEVELOPMENT The drug development arm of Johnson & Johnson (JNJ) has teamed up with an medical research facility called the Sanford - Burnham Institute in the hopes that the partnership will shorten the path to getting new Alzheimer's treatments FDA approdrug development arm of Johnson & Johnson (JNJ) has teamed up with an medical research facility called the Sanford - Burnham Institute in the hopes that the partnership will shorten the path to getting new Alzheimer's treatments FDA approval.

In January 2017, SiteOne announced the closing of a research and development agreement with Amgen, a collaboration focused on combining SiteOne's experienced drug discovery team and portfolio of novel Naᵥ1.7 inhibitors with Amgen's neuroscience capabilities.

«It essentially gives us a periodic table,» Ron DePinho, President of MD Anderson Cancer Center says, which has provided us with both diagnostic and therapeutic value as well as helped us design clinical trials to accelerate the development of new cancer drugs,».

Using its proprietary antisense technology, Ionis has created a large pipeline of first - in - class or best - in - class drugs, with over 40 drugs in development.

But rather than buying up a genetic research outfit, it decided to build its own in the form of the Regeneron Genetics Center (RGC), an ambitious four - year old effort to sequence as many exomes (the protein - encoding part of the genome) as possible, pair them with medical records, and accelerate drug development.

Perhaps this will include research and development of drugs for other diseases, albeit with fewer researchers, but to date, neither the amount the company will save nor its specific use of these freed - up resources has been detailed.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Alnylam $ ALNY may be going solo on the development of rare disease drug lumasiran after Sanofi took a pass on its option, but the FDA has come through with a major assist.

Frustrated with the lack of investment in research and drug development devoted to pediatric brain tumor gliomas, the Kamens decided to take action and launch their foundation.

Sierra Oncology, Inc., a clinical stage drug development company focused on advancing next - generation DNA damage response therapeutics for the treatment of patients with cancer, went public near $ 29 in July 2015, then began a downtrend that continued through a June 2017 all - time low of $ 1.10.

This designation enables Aura to have more frequent interactions with the FDA throughout AU - 011's drug development process, as well as priority review of the New Drug Application (Ndrug development process, as well as priority review of the New Drug Application (NDrug Application (NDA).

The Minoryx team is made up of a group of drug discovery and development experts with several decades of experience in biotech and pharma.

Represented European based biotech company, focused on drug delivery solutions, with respect to its inbound and outbound licensing transactions and those related to the development, manufacture and supply of key components of its technologies.

Triphase Accelerator Corporation announced a new strategic collaboration with Celgene Corporation, that provides Celgene with an option to acquire all Triphase Accelerator's assets relating to TRPH 222 (CD22 - 4AP), an antibody - drug conjugate in development for lymphoma.

VICTORIA — New Democrats are demanding answers from the Christy Clark government following reports that children involved with the Ministry of Children and Family Development were staying at a known drug den in Prince George.

Accordingly, some drug manufacturers, flush with cash, attempt to acquire smaller companies — and their pipeline of drugs under research and development.

What looks like a bubble at first glance can be viewed as a long - term strategy for funding drug development, one that involves private funds, pharmaceutical companies and the public markets, along with a good deal of risk — and, sometimes, high reward.

Douglas Loe, healthcare equity analyst with Echelon Wealth Partners, brings more than a decade of experience to financial analysis in the global drug development, medical technology, healthcare services and specialty pharmaceutical sectors.

MaRS Innovation (MI) and the Centre for Drug Research and Development (CDRD) are pleased to announce that they have entered into an agreement to collaborate on projects of mutual interest with a goal to advance and commercialize early - stage health - related discoveries.

This includes a stem cell research centre, a network of drug discovery institutes and a # 20 million global clinical development fund dedicated to supporting Phase I and II clinical trials; and a # 2 million collaboration between University of Cambridge and University College London that will use donated cells from people with Alzheimer's to test potential new treatments

The company announced agreements to use the Oncomine Dx Target Test in drug development programs with Daiichi Sankyo, Takeda, and Spectrum Pharmaceuticals.

According to the Greens, since these drugs interfere with implantation in the womb, they destroy human life in the earliest stage of development.

Assisting athletes in coping with sport - specific expectations, injury, anxiety, depression, conflict, communication with coaches, social media, alcohol or drug use, game - related pressure, sexual assault, athletic identity and other areas is vital to the personal development of youth athletes.

The American Academy of Pediatrics advises against the use of marijuana during pregnancy and while breastfeeding: «Street drugs such as PCP (phencyclidine), cocaine, and cannabis can be detected in human milk, and their use by breastfeeding mothers is of concern, particularly with regard to the infant's long - term neurobehavioral development and thus are contraindicated.»

A licensed Marriage and Family Therapist, Agnes spent several years working with AADAP (Asian American Drug Abuse Program), the Asian Pacific Mental Health Clinic and Shanti (Aids counseling) before coming to ECPC in 1995 for training in early childhood development.

The HMBANA guidelines, developed with the assistance of the Food and Drug Administration (FDA), the Center for Disease Control (CDC) and the American Academy of Pediatrics (AAP), have been used globally in the development of nearly all milk banking standards and are reviewed annually to ensure safety.

less than or equal to lamivudine Acquired Immune Deficiency Syndrome Antiretroviral therapy, usually means 1 - 2 drugs, used in early studies Antiretroviral zidovudine (also known as ZDV) Breastfeeding Baby Friendly Hospital Initiative Breastfeeding and HIV International Transmission Study Combined antiretroviral therapy Centers for Disease Control and Prevention Deoxyribonucleic Acid Exclusive Breastfeeding Enzyme Linked Immunosorbent Assay Food and Agrigulture Organization Fixed dose combination ART, e.g., lamividine, stavudine, and nevirapine Highly Active Antiretroviral Therapy, 3 or more drugs for more effective treatment used in later studies Human Immunodeficiency virus International Atomic Energy Agency Infant feeding Infant and young child feeding Lopinavir cubic millimetre Mother - to - Child Transmission of HIV Non-governmental organization Nevirapine Polymerase Chain Reaction People Living with HIV Prevention of Mother - to - Child Transmission Replacement Feeding Ritonavir Ribonucleic acid, one of the three major macromolecules (along with DNA and proteins) that are essential for all known forms of life single dose NVP United Nations Agencies Joint United Nations Programme on HIV / AIDS United Nations Population Fund United Nations Commissioner for Refugees United Nations Children's Fund U.S. Agency for International Development World Alliance for Breastfeeding Action United Nations World Food Programme World Health Assembly WHO 2010 Guidelines on HIV and infant feeding World Health Organization Zidovudine (same drug as AZT)

With the advancements in technology in almost all aspects of life, the strides made in reproductive technology have led to the development of drugs that can stimulate ovulation.

Physical punishment is associated with a range of mental health problems in children, youth and adults, including depression, unhappiness, anxiety, feelings of hopelessness, use of drugs and alcohol, and general psychological maladjustment.26 — 29 These relationships may be mediated by disruptions in parent — child attachment resulting from pain inflicted by a caregiver, 30,31 by increased levels of cortisol32 or by chemical disruption of the brain's mechanism for regulating stress.33 Researchers are also finding that physical punishment is linked to slower cognitive development and adversely affects academic achievement.34 These findings come from large longitudinal studies that control for a wide range of potential confounders.35 Intriguing results are now emerging from neuroimaging studies, which suggest that physical punishment may reduce the volume of the brain's grey matter in areas associated with performance on the Wechsler Adult Intelligence Scale, third edition (WAIS - III).36 In addition, physical punishment can cause alterations in the dopaminergic regions associated with vulnerability to the abuse of drugs and alcohol.37

«Baroness Smith of Basildon to move that this House regrets that Her Majesty's Government's plans for the introduction of the draft Misuse of Drugs Act 1971 (Amendment)(No. 2) Order 2014 do not include provisions for a 12 - month review of the impact of the reclassification of khat in view of the highly unusual community focus of its use, for putting a detailed policing strategy in place before a ban takes effect, or for a health strategy to prevent a transfer of addiction to other substances; and do not commit the Department for International Development to do more work with the government of Kenya to alleviate the effect of the reclassification on the Kenyan economy.»

As with any such intentions, the actual rules are gamed, resulting in excessive prices in the US (especially for so - called orphan drugs) while claims that this system is necessary for further development of new drugs are not empirically supported.

Citing improvements in town administration, a ban on synthetic drugs and cancellation of a tax agreement with a controversial affordable housing development in Glasco, Town Supervisor Kelly Myers announced her candidacy for a second term last week.

Although hormonal growth promoters are illegal in the UK, it is widely feared that the use of antibiotics may be contributing towards the development of drug - resistant bacteria, with potentially serious consequences for animal and human health.

This time I also requested records documenting the selection of LP Ciminelli and Ciminelli Real Estate — separate companies owned by brothers — to build space at the Conventus Building on the Buffalo Niagara Medical Campus to accommodate AMRI, a drug research and development firm recruited with $ 50 million in Buffalo Billion money.

Over the past year, Kaloyeros has been working with local officials, including those at the Buffalo Niagara Medical Campus, to develop plans announced by Cuomo in December to invest $ 50 million in state funds to build and equip a pharmaceutical drug research and development center at the downtown medical campus.

The new investigation is focused on the multimillion - dollar contracts awarded to build facilities for high - tech, drug - development and clean - energy businesses, a source familiar with the probe told The Post.

The University of Tokyo conducts world - class interdisciplinary research, emphasizing translational applications and drug development with its new facilities.

Moreover, the findings, if replicated in his and others» ongoing studies, could spur development of drugs that target HDL subclasses, working to raise HDL without apoC - III and lower HDL with it.

A controversial study infects people with schistosomiasis to speed up drug and vaccine development.

We are indebted to my colleague, Nancy Kuntz, MD, and co-author laboratories of Drs. Jasbir Singh and Mike Kiledjian along with Repligen and Families of Spinal Muscular Atrophy (FSMA), who initiated the development of this drug candidate.

Researchers from the UK and Denmark have developed a new method to predict the physical stability of drug candidates, which could help with the development of new and more effective medicines for patients.

In addition, risks associated with the usability, therapeutic efficacy and market share of medicinal substances are usually realized only in the final stages of drug development.